BIOQUAL Declares Dividend

Rhea-AI Summary

BIOQUAL declares dividend of $0.50 per share, 22nd dividend declared. Forward-looking statements caution investors. Risks include contract extensions, obtaining new contracts, demand for animal models, employee availability, contract performance, costs management, dependence on third parties, capital needs, financing availability and cost.

Positive

• BIOQUAL declares dividend of $0.50 per share
• Continued demand for animal models in scientific research

Negative

• Risks in contract extensions and obtaining new contracts
• Dependence on third parties and financing availability and cost

ROCKVILLE, Md.--(BUSINESS WIRE)-- BIOQUAL’s Board of Directors has declared a dividend of $0.50 per share for shareholders of record on October 6, 2023, payable on October 27, 2023. This is the twenty-second dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230922398688/en/

Mark G. Lewis, Ph.D., CEO (240-404-7654)

Source: BIOQUAL, Inc.